Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate

Vaccine

Volumn 29, Issue 21, 2011, Pages 3802-3810

  Eko, F O ^a   Okenu, D N ^a   Singh, U P ^a,b   He, Q ^a   Black, C ^c   Igietseme, J U ^a,c  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Chlamydia; Cholera; Combination vaccine; Cross protection

Indexed keywords

RECOMBINANT VIBRIO CHOLERAE GHOST; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHOLERA; CONTROLLED STUDY; CROSS PROTECTION; DISEASE MARKER; FEMALE; GENITAL SYSTEM; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; MOUSE STRAIN; MUCOSA; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; TH1 CELL; VIBRIO CHOLERAE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL PROTEINS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHOLERA; CROSS PROTECTION; CYTOKINES; DRUG EVALUATION; FEMALE; GENETIC VECTORS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PORINS; VACCINES, COMBINED; VACCINES, SUBUNIT; VIBRIO CHOLERAE;

EID: 79955083821     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.027     Document Type: Article

References (56)

1. Schachter J., Grayston J.T. Epidemiology of human chlamydial infections. Chlamydial infections 1998, 3-10. Berkeley, San Francisco, CA. R.S. Stephens, G.I. Byrne, G. Christiansen, I.N. Clarke, J.T. Grayston, R.G. Rank (Eds.).
2. Brunham R.C., Zhang D.J. Transgene as vaccine for Chlamydia. Am Heart J 1999, 138:S519-S522.
3. Singh V., Salhan S., Das B.C., Mittal A. Predominance of Chlamydia trachomatis serovars associated with urogenital infections in females in New Delhi, India. J Clin Microbiol 2003, 41(6):2700-2702.
4. Gao X., Chen X.-S., Yin Y.-P., Zhong M.-Y., Shi M.-Q., Wei W.-H., et al. Distribution study of Chlamydia trachomatis serovars among high-risk women in China performed using PCR-restriction fragment length polymorphism genotyping. J Clin Microbiol 2007, 45(4):1185-1189.
5. Petrovay F., Balla E., Nemeth I., Gonczol E. Genotyping of Chlamydia trachomatis from the endocervical specimens of high-risk women in Hungary. J Med Microbiol 2009, 58(6):760-764.
6. Lima H.E.M., Oliveira M.B.P., Valente B.G.M., Afonso D.A.F.P., DaRocha W.D.P., Souza MCMdP, et al. Genotyping of Chlamydia trachomatis from endocervical specimens in Brazil. Sex Transm Dis 2007, 34(9):709-717.
7. Igietseme J.U., Eko F.O., Black C.M. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines 2003, 2(1):129-146.
8. Stagg A.J. Vaccines against Chlamydia: approaches and progress. Mol Med Today 1998, 4(4):166-173.
9. Morrison R., Caldwell H. Immunity to murine chlamydial genital infection. Infect Immun 2002, 70(6):2741-2751.
10. Brunham R.C., Peeling R.W. Chlamydia trachomatis antigens: role in immunity and pathogenesis. Infect Agents Dis 1994, 3:218-233.
11. Su H., Parnell M., Caldwell H.D. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against genital tract infection. Vaccine 1995, 13(11):1023-1032.
12. Eko F., Lubitz W., McMillan L., Ramey K., Moore T., Ananaba G.A., et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 2003, 21:1694-1703.
13. Pal S., Theodor I., Peterson E.M., de la Maza L.M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 2001, 69(10):6240-6247.
14. He Q., M-Sobrido L., Eko F.O., Palese P., Garcia-Sastre A., Lyn D., et al. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology 2007, 122(1):28-37.
15. Stephens R.S., Kalman S., Lammel C., Fan J., Marathe R., Aravind L., et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 1998, 282(5389):754-759.
16. Stephens R.S. Chlamydial genomics and vaccine antigen discovery. J Infect Dis 2000, 181(Suppl. 3):S521-S523.
17. Grimwood J., Olinger L., Stephens R.S. Expression of Chlamydia pneumoniae polymorphic membrane protein family genes. Infect Immun 2001, 69(4):2383-2389.
18. Niessner A., Kaun C., Zorn G., Speidl W., Türel Z., Christiansen G., et al. Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway. J Infect Dis 2003, 188(1):108-113.
19. Kubo A., Stephens R.S. Characterization and functional analysis of PorB, a Chlamydia porin and neutralizing target. Mol Microbiol 2000, 38(4):772-780.
20. Crane D.D., Carlson J.H., Fischer E.R., Bavoil P., Hsia R-c, Tan C., et al. From the cover: Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. PNAS 2006, 103(6):1894-1899.
21. Ifere G., He Q., Ananaba G., Lyn D., Lubitz W., Kellar K., et al. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect 2007, 40:188-200.
22. Eko F.O., He Q., Brown T., McMillan L., Ifere G.O., Ananaba G.A., et al. A novel recombinant multisubunit vaccine against Chlamydia. J Immunol 2004, 173(5):3375-3382.
23. Carpenter C. The treatment of cholera: clinical science on the bedside. J Infect Dis 1992, 166:2-14.
24. Ivers L.C., Farmer P., Almazor C.P., Leandre F. Five complementary interventions to slow cholera: Haiti. Lancet 2010, 376(9758):2048-2051.
25. Mekalanos J., Waldor M., Gardel C., Coster T., Kenner J., Killeen K., et al. Live cholera vaccines: perspectives on their construction and safety. Bull Inst Pasteur 1995, 93:255-262.
26. Grandjean C., Boutonnier A., Dassy B., Fournier J.M., Mulard L.A. Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba. Glycoconj J 2009, 26(1):41-55.
27. Attridge S., Voss E., Manning P. Pathogenic and vaccine significance of toxin-coregulated pili of Vibrio cholerae El Tor. J Biotechnol 1999, 73(2-3):109-117.
28. Levine M., Tacket C. Recombinant live cholera vaccines. Vibrio cholerae and cholera. Molecular to global perspectives 1994, 395-413. ASM Press, Washington. I. Wachsmuth, P. Blake, O. Olsvik (Eds.).
29. Eko F.O., Witte A., Huter V., Kuen B., Furst-Ladani S., Haslberger A., et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 1999, 17:1643-1649.
30. Eko F.O., Mayr U.B., Attridge S.R., Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J Biotechnol 2000, 83:115-123.
31. Eko F.O., Schukovskaya T., Lotzmanova E.Y., Firstova V.V., Emalyanova N.V., Klueva S.N., et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 2003, 21(25-26):3663-3674.
32. Macmillan L., Ifere G., He Q., Igietseme J., Kellar K., Okenu D., et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol 2007, 49:46-55.
33. Igietseme J.U., Rank R.G. Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract. Infect Immun 1991, 59:1346-1351.
34. Eko F., Ekong E., Okenu D., He Q., Ananaba G., Black C., et al. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine 2011, 29(7):1472-1480.
35. Kawa D.E., Stephens R.S. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J Immunol 2002, 168(10):5184-5191.
36. Kawa D.E., Schachter J., Stephens R.S. Immune response to the Chlamydia trachomatis outer membrane protein PorB. Vaccine 2004, 22(31-32):4282-4286.
37. Wehrl W., Brinkmann V., Jungblut P.R., Meyer T.F., Szczepek A.J. From the inside out - processing of the chlamydial autotransporter PmpD and its role in bacterial adhesion and activation of human host cells. Mol Microbiol 2004, 51(2):319-334.
38. Murthy A.K., Chambers J.P., Meier P.A., Zhong G., Arulanandam B.P. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun 2007, 75(2):666-676.
39. Scriba T.J., Kalsdorf B., Abrahams D.-A., Isaacs F., Hofmeister J., Black G., et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008, 180(3):1962-1970.
40. Pitta M.G.R., Romano A., Cabantous S., Henri S., Hammad A., Kouriba B., et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest 2009, 119(8):2379-2387.
41. Zhang X., Gao L., Lei L., Zhong Y., Dube P., Berton M.T., et al. A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol 2009, 183(2):1291-1300.
42. Zhou X., Chen Q., Moore J., Kolls J.K., Halperin S., Wang J. Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species. Infect Immun 2009, 77(11):5059-5070.
43. Bai H., Cheng J., Gao X., Joyee A.G., Fan Y., Wang S., et al. IL-17/Th17 promotes Type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J Immunol 2009, 183(9):5886-5895.
44. Jha R., Srivastava P., Salhan S., Finckh A., Gabay C., Mittal A., et al. Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infection. Microbes Infect 2011, 13(2):167-178.
45. Igietseme J.U., Uriri I.M., Kumar S.N., Ananaba G.A., Ojior O.O., Momodu I.A., et al. Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun 1998, 66(9):4030-4035.
46. Moore T., Ananaba G.A., Bolier J., Bowers S., Belay T., Eko F.O., et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 2002, 105(2):213-221.
47. Igietseme J.U., Eko F.O., He Q., Black C.M. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004, 3(1):23-34.
48. Morrison S., Morrison R. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005, 175(11):7536-7542.
49. Li W., Guentzel M.N., Seshu J., Zhong G., Murthy A.K., Arulanandam B.P. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin Vaccine Immunol 2007, 14(12):1537-1544.
50. Mader H.J., Szostak M.P., Hensel A., Lubitz W., Haslberger A.G. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 1997, 15(2):195-202.
51. Clemens J., Sack D., Harris vL F., Chakraborty J., Ahmed F., Rao M., et al. Field trial of oral cholera vaccines in Bangladesh: results from three year follow-up. Lancet 1990, 335:270-273.
52. Anh D.D., Canh D.G., Lopez A.L., Thiem V.D., Long P.T., Son N.H., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007, 25(6):1149-1155.
53. Attridge S.R., Rowley D. Prophylactic significance of non-lipopolysaccharide antigens of Vibrio cholerae. J Infect Dis 1983, 148:931-939.
54. Winner L., Mack J., Weltzin R., Mekalanos J., Kraehenbuhl J.-P., Neutra M. New model for analysis of mucosal immunity:intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infect Immun 1991, 59:977-982.
55. Jertborne M., Svennerholm A.-M., Holmgren J. Saliva, breast milk and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol 1986, 24:202-209.
56. Clemens J., van Loon F., Sack D., Chakraborty J., Rao M., Ahmed F., et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 1991, 163:1235-1242.